RxDoctor Payments Data

Frederick Buckner

Infectious Disease · Seattle, WANPI 1497845358

Payments from drug & device makers

What this record shows

That places this record below the midpoint for infectious disease clinicians in WA, where the typical reported total is $77.

No general payments reported

No drug or device maker reported general payments to this provider for 2019–2025. That is a common and unremarkable result.

$273,131in research payments, 2019–2025

Across 8 payments — averaging $34,141 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cerus Corporation$273K

How this compares

$0 in reported general payments places this provider in the 20th percentile of 186 infectious disease providers in Washington.

See all infectious disease providers in Washington

Medicare billing

Part B allowed, 2024
$10,523
Medicare patients
42
Services billed
103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gentamicin Sulfate16$1,756
Azithromycin12$638

Paid to pharmacies, not to this prescriber.

Other infectious disease in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →